Immutep: GlaxoSmithKline Discontinues Phase II Study On Ulcerative Colitis
LONDON (dpa-AFX) - Immutep Limited (IMMP) said that its licensing partner GlaxoSmithKline plc. (GSK.L, GSK) has discontinued its Phase II clinical trial evaluating an anti-LAG3 cell depleting monoclonal antibody, GSK2831781, in patients with active ulcerative colitis.
GlaxoSmithKline stopped the trial based on the assessment of clinical data as part of a planned interim analysis conducted in consultation with the trial s Data Review Committee.
However, GSK is conducting further reporting, assessment and analyses of the efficacy and safety data and evaluating the biology to determine next steps for the GSK2831781 development program.
TACTI-002 study expanded in lung cancer
New phase II trial in head and neck cancer announced
EOC Pharma starts new phase II study in metastatic breast cancer
Robust operational and financial position, with $54.9 million in cash as at 31 December 2020, providing cash runway beyond the end of calendar year 2022
Sydney, AUSTRALIA, Jan. 22, 2021 (GLOBE NEWSWIRE) Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti” or “IMP321”) and IMP761, and the activities of its partners.
iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), Acasti Pharma (NASDAQ:ACST) - The Daily Biotech Pulse: Fluidigm s Saliva-Based COVID Test Approved In Europe, China Backs Amarin s Vascepa benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.